Eli Lilly and Company (LLY) Receives ‘Analyst’ Rating

Eli Lilly and Company (LLY) : 15 analysts are covering Eli Lilly and Company (LLY) and their average rating on the stock is 1.67, which is read as a Buy. 11 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Eli Lilly and Company (LLY) : The highest short term price target forecast on Eli Lilly and Company (LLY) is $116 and the lowest target price is $55. A total of 12 equity analysts are currently covering the company. The average price of all the analysts is $95.67 with a standard deviation of $16.34.


Also, In a research note released to the investors, JP Morgan upgrades its rating on Eli Lilly and Company (NYSE:LLY).The analysts at the brokerage house have a current rating of Overweight on the shares. Earlier, the shares were rated a Neutral by the brokerage firm. The rating by the firm was issued on September 8, 2016.

Eli Lilly and Company (NYSE:LLY): After opening at $78.12, the stock dipped to an intraday low of $77.77 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $79.06 and the buying power remained strong till the end. The stock closed at $78.82 for the day, a gain of 0.68% for the day session. The total traded volume was 2,653,694. The stocks close on the previous trading day was $78.29.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.